



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not file a collection of information unless it contains a valid OMB control number.

<p>Substitute for Form PTO-891 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>	Complete if Known				
	Application Number	10/761,435			
	Filing Date	January 22, 2004			
	First Named Inventor	UMAÑA, Pablo			
	Art Unit	1633			
	Examiner Name	Burkhart, Michael D.			
Sheet	1	of	1	Attorney Docket Number	1975.0180003/TJS/M-N

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	WO 94/11026 A2	05/26/1994	Idec Pharmaceuticals Corporation		
	FP2	WO 96/40210 A1	12/19/1996	Imclone System Inc.; MRC Collaborative Centre; Goldstein <i>et al.</i>		
	FP3	WO 01/29242 A2	04/26/2001	Monsanto Company		

762243v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	1	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	NPL1	Amigorena, S., "Fc γ Receptors and Cross-Presentation in Dendritic Cells," <i>J. Exp. Med.</i> 195:F1-F3, The Rockefeller University Press (January 2002)		
	NPL2	Andersen, D.C., and Krummen, L., "Recombinant protein expression for therapeutic applications," <i>Curr. Opin. Biotechnol.</i> 13:117-123, Elsevier Science Ltd. (April 2002)		
	NPL3	Arnon, R., <i>et al.</i> , "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy," in <i>Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld, R.A., and Sell, S., eds., Alan R. Liss, Inc., New York, NY, pp. 243-256 (1985)		
	NPL4	Borth, N., <i>et al.</i> , "Efficient Selection of High-Producing Subclones During Gene Amplification of Recombinant Chinese Hamster Ovary Cells by Flow Cytometry and Cell Sorting," <i>Biotechnol. Bioeng.</i> 71:266-273, John Wiley & Sons, Inc. (2001)		
	NPL5	Carson, W.E., <i>et al.</i> , "Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells," <i>Eur. J. Immunol.</i> 31:3016-3025, Wiley-VCH Verlag GmbH (2001)		
	NPL6	Cartron, G., <i>et al.</i> , "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc γ RIIIa gene," <i>Blood</i> 99:754-758, American Society of Hematology (February 2002)		
	NPL7	Chadd, H.E., and Chamow, S.M., "Therapeutic antibody expression technology," <i>Curr. Opin. Biotechnol.</i> 12:188-194, Elsevier Science Ltd. (2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	2	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL8	Chamow, S.M., and Ashkenazi, A., "Immunoadhesins: principles and applications," <i>Trends Biotechnol.</i> 14:52-60, Elsevier Science Ltd. (1996)	
	NPL9	Clynes, R.A., <i>et al.</i> , "Inhibitory Fc receptors modulate <i>in vivo</i> cytotoxicity against tumor targets," <i>Nat. Med.</i> 6:443-446, Nature Publishing Company (2000)	
	NPL10	Cole, S.P.C., <i>et al.</i> , "The EBV-Hybridoma Technique and Its Applications to Human Lung Cancer," in <i>Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld, R.A., and Sell, S., eds., Alan R. Liss, Inc., New York, NY, pp. 77-96 (1985)	
	NPL11	Colbère-Garapin, F., <i>et al.</i> , "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells," <i>J. Mol. Biol.</i> 150:1-14, Academic Press Inc. (London) Ltd. (1981)	
	NPL12	Cote, R.J., <i>et al.</i> , "Generation of human monoclonal antibodies reactive with cellular antigens," <i>Proc. Natl. Acad. Sci. USA</i> 80:2026-2030, The National Academy of Sciences (1983)	
	NPL13	Cragg, M.S., <i>et al.</i> , "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts," <i>Blood</i> 101:1045-1052, The American Society of Hematology (February 2003)	
	NPL14	Cumming, D.A., "Glycosylation of recombinant protein therapeutics: control and functional implications," <i>Glycobiology</i> 1:115-130, Oxford University Press (1991)	
	NPL15	Daëron, M., "Fc Receptor Biology," <i>Annu. Rev. Immunol.</i> 15:203-234, Annual Reviews Inc. (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
Sheet	3	of	10	Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
				Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL16	de Haas, M., <i>et al.</i> , "A Triallelic Fcγ Receptor Type IIIA Polymorphism Influences the Binding of Human IgG by NK Cell FcγRIIIa ¹ ," <i>J. Immunol.</i> 156:2948-2955, The American Association of Immunologists (1996)	
	NPL17	Deo, Y.M., <i>et al.</i> , "Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies," <i>Immunol. Today</i> 18:127-135, Elsevier Science Ltd. (1997)	
	NPL18	Dillman, R.O., "Magic Bullets at Last! Finally-Approval of a Monoclonal Antibody for the Treatment of Cancer!!!," <i>Cancer Biother. Radiopharm.</i> 12:223-225, Mary Ann Liebert, Inc. (1997)	
	NPL19	Freireich, E.J., <i>et al.</i> , "Quantitative Comparison of Toxicity of AntiCancer Agents in Mouse, Rats, Hamster, Dog, Monkey, and Man," <i>Cancer Chemother. Rep.</i> 50:219-244, National Cancer Institute (1966)	
	NPL20	Frost, J.D., <i>et al.</i> , "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 in Children with Refractory Neuroblastoma," <i>Cancer</i> 80:317-333, John Wiley & Sons, Inc. (1997)	
	NPL21	Giddings, G., "Transgenic plants as protein factories," <i>Curr. Opin. Biotechnol.</i> 12:450-454, Elsevier Science Ltd. (2001)	
	NPL22	Goldenberg, M.M., "Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer," <i>Clin. Ther.</i> 21:309-318, Excerpta Medica, Inc. (1999)	
	NPL23	Grillo-López, A.J., <i>et al.</i> , "Overview of the Clinical Development of Rituximab: First Monoclonal Antibody Approved for the Treatment of Lymphoma," <i>Semin. Oncol.</i> 26:66-73, W.B. Saunders Company (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	4	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	NPL24	Hartman, S.C., and Mulligan, R.C., "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," <i>Proc. Natl. Acad. Sci. USA</i> 85:8047-8051, National Academy of Sciences (1988)			
	NPL25	Hazenbos, W. L. W., <i>et al.</i> , "Murine IgG1 Complexes Trigger Immune Effector Functions Predominantly via Fc γ RIII (CD16)," <i>J. Immunol.</i> 161:3026-3032, The American Association of Immunologists (1998)			
	NPL26	Hellström, K.E., and Hellström, I., "Chap. 15. Antibodies for Drug Delivery," <i>Controlled Drug Delivery Fundamentals and Applications</i> , 2 nd ed., Robinson, J.R., and Lee, V.H.L., eds., Marcel Dekker, Inc., New York, NY, pp. 623-653 (1987)			
	NPL27	Huse, W.D., <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> 246:1275-1281, American Association for the Advancement of Science (1989)			
	NPL28	Jefferis, R., <i>et al.</i> , "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," <i>Immunol. Rev.</i> 163:59-76, Munksgaard (1998)			
	NPL29	Jenkins, N., <i>et al.</i> , "Getting the glycosylation right: Implications for the biotechnology industry," <i>Nat. Biotechnol.</i> 14:975-981, Nature America Publishing (1996)			
	NPL30	Kalergis, A.M., and Ravtech, J.V., "Inducing Tumor Immunity through the Selective Engagement of Activating Fc γ Receptors on Dendritic Cells," <i>J. Exp. Med.</i> 195:1653-1659, The Rockefeller University Press (June 2002)			
	NPL31	Kobayashi, N., <i>et al.</i> , "Analysis of Assembly of Synthetic Antibody Fragments: Expression of Functional scFv with Predefined Specificity," <i>BioTech.</i> 23:500-503, Eaton Publishing Co. (1997)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	5	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL32	Köhler, G., and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> 256:495-497, Macmillan Journals Ltd. (1975)	
	NPL33	Kozbor, D., and Roder, C.J., "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> 4:72-79, Elsevier Biomedical Press (1983)	
	NPL34	Lerouge, P., <i>et al.</i> , "N-Glycosylation of Recombinant Pharmaceutical Glycoproteins Produced in Transgenic Plants: Towards an Humanisation of Plant N-Glycans," <i>Curr. Pharm. Biotechnol.</i> 1:347-354, Bentham Science Publishers Ltd. (2000)	
	NPL35	Lifely, M.R., <i>et al.</i> , "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions," <i>Glycobiology</i> 5:813-822, Oxford University Press (1995)	
	NPL36	Lis, H., and Sharon, N., "Protein glycosylation Structural and Functional aspects," <i>Eur. J. Biochem.</i> 218:1-27, FEBS (1993)	
	NPL37	Lowy, I., <i>et al.</i> , "Isolation of Transforming DNA: Cloning the Hamster aprt Gene," <i>Cell</i> 22:817-823, MIT (1980)	
	NPL38	Lund, J., <i>et al.</i> , "Multiple Interactions of IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains," <i>J. Immunol.</i> 157:4963-4969, American Association of Immunologists (1996)	
	NPL39	Ma, J. K.-C., <i>et al.</i> , "The Production of Recombinant Pharmaceutical Proteins in Plants," <i>Nat. Rev. Genet.</i> 4:794-805, Nature Publishing Group (October 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	6	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL40	Maloney, D.G., <i>et al.</i> , "Rituximab: Mechanism of Action and Resistance," <i>Semin. Oncol.</i> 29:2-9, W.B. Saunders Company (February 2002)	
	NPL41	Metes, D., <i>et al.</i> , "Identification of the CD32/Fc γ RIIc-Q ¹³ /STP ¹³ polymorphism using an allele-specific restriction enzyme digestion assay," <i>J. Immunol. Meth.</i> 258:85-95, Elsevier Science B.V. (2001)	
	NPL42	Mulligan, R.C., and Berg, P., "Selection for animal cells that express the <i>Escherichia coli</i> gene coding for xanthine-guanine phosphoribosyltransferase," <i>Proc. Natl. Acad. Sci. USA</i> 78:2072-2076, National Academy of Science (1981)	
	NPL43	Morrison, S.L., <i>et al.</i> , "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855, National Academy of Science (1984)	
	NPL44	Neuberger, M.S., <i>et al.</i> , "Recombinant antibodies possessing novel effector functions," <i>Nature</i> 312:604-608, Macmillan Journals Ltd. (1984)	
	NPL45	Nilsson, T., <i>et al.</i> , "Kin recognition between <i>medial</i> Golgi enzymes in HeLa cells," <i>EMBO J.</i> 13:562-574, Oxford University Press (1994)	
	NPL46	O'Hare, K., <i>et al.</i> , "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase," <i>Proc. Natl. Acad. Sci. USA</i> 78:1527-1531, National Academy of Science (1981)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	7	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		
	NPL47	Opat, A.S., <i>et al.</i> , "Medial Golgi but Not Late Golgi Glycosyltransferases Exist as High Molecular Weight Complexes," <i>J. Biol. Chem.</i> 275:11836-11845, The American Society for Biochemistry and Molecular Biology, Inc. (2000)		T ²
	NPL48	Order, S.E., "Chap. 15. Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy," in <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Baldwin, R.W., and Byers, V.S., eds., Academic Press Inc. (London) Ltd., pp. 303-316 (1985)		
	NPL49	Pini, A., <i>et al.</i> , "Design and Use of a Phage Display Library," <i>J. Biol. Chem.</i> 273:21769-21776, The American Society for Biochemistry and Molecular Biology, Inc. (1988)		
	NPL50	Rabouille, C., <i>et al.</i> , "Mapping the distribution of Golgi enzymes involved in the construction of complex oligosaccharides," <i>J. Cell Sci.</i> 108:1617-1627, The Company of Biologist Ltd. (1995)		
	NPL51	Ratanatharathorn, V., <i>et al.</i> , "Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Hot Disease," <i>Ann. Intern. Med.</i> 133:275-279, The American College of Physician-American Society of Internal Medicine (2000)		
	NPL52	Ravetch, J.V., and Bolland, S., "IgG Fc Receptors," <i>Annu. Rev. Immunol.</i> 19:275-290, Annual Reviews (2001)		
	NPL53	Reff, M.E., and Heard, C., "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications," <i>Crit. Rev. Oncol. Hematol.</i> 40:25-35, Elsevier Science Ireland Ltd. (2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet 8		of 10	Attorney Docket Number 1975.0180003/TJS/M-N		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL54	Santerre, R.F., <i>et al.</i> , "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells," <i>Gene</i> 1069:147-156, Elsevier Science Publishers (1984)	
	NPL55	Schachter, H., "Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides," <i>Biochem. Cell Biol.</i> 64:163-181, National Research Council of Canada (1986)	
	NPL56	Selenko, N., <i>et al.</i> , "Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?", <i>J. Clin. Immunol.</i> 22:124-130, Plenum Publishing Corporation (May 2002)	
	NPL57	Senter, P.D., "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy," <i>FASEB J.</i> 4:188-193, Federation of American Societies for Experimental Biology (1990)	
	NPL58	Senter, P.D., <i>et al.</i> , "Enhancement of the <i>in Vitro</i> and <i>in Vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates," <i>Cancer Res.</i> 49:5789-5792, American Association for Cancer Research, Inc. (1989)	
	NPL59	Senter, P.D., <i>et al.</i> , "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <i>Proc. Natl. Acad. Sci. USA</i> 85:4842-4846, The National Academy of Sciences (1988)	
	NPL60	Shields, R.L., <i>et al.</i> , "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fc γ RIII and Antibody-dependent Cellular Toxicity," <i>J. Biol. Chem.</i> 277:26733-26740, The American Society for Biochemistry and Molecular Biology, Inc. (July 2002)	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
				Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
Sheet	9	of	10	Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		
T ²				
	NPL61	Stabila, P.F., <i>et al.</i> , "Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors," <i>Nat. Biotechnol.</i> 16:1357-1360, Nature American Inc. (1998)		
	NPL62	Surfus, J.E., <i>et al.</i> , "Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors," <i>J. Immunother.</i> 19:184-191, Lippincott-Raven Publishers (1996)		
	NPL63	Szybalska, E.H., and Szybalski, W., "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>Proc. Natl. Acad. Sci. USA</i> 48:2026-2034, National Academy of Science (1962)		
	NPL64	Takeda, S.-I., <i>et al.</i> , "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> 314:452-454, Macmillan Journals Ltd. (1985)		
	NPL65	Thorpe, P.E., and Ross, W.C.J., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates," <i>Immunol. Rev.</i> 62:119-158, Munksgaard (1982)		
	NPL66	Thorpe, P.E., "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review," in <i>Monoclonal Antibodies '84: Biological and Clinical Applications</i> , Pinchea, A., <i>et al.</i> , eds., Editrice Kurtis, Italy, Milano, pp. 475-506 (1985)		
	NPL67	Umaña, P., <i>et al.</i> , "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity," <i>Nat. Biotechnol.</i> 17:176-180, Nature America, Inc. (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/761,435
Sheet	10	of	10	Filing Date	January 22, 2004
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	Burkhart, Michael D.
				Attorney Docket Number	1975.0180003/TJS/M-N

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL68	van Der Kolk, L.E., <i>et al.</i> , "Complement activation plays a key role in the side-effects of rituximab treatment," <i>Br. J. Hematol.</i> 115:807-811, Blackwell Science Ltd. (2001)		
	NPL69	Werner, R.G., <i>et al.</i> , "Appropriate Mammalian Expression Systems for Biopharmaceuticals," <i>Arzneim.-Forsch./Drug Res.</i> 48:870-880, Editio Cantor Verlages (1998)		
	NPL70	Wigler, M., <i>et al.</i> , "Transformation of mammalian cells with an amplifiable dominant-acting gene," <i>Proc. Natl. Acad. Sci. USA</i> 77:3567-3570, National Academy of Science (1980)		
	NPL71	Wigler, M., <i>et al.</i> , "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," <i>Cell</i> 11:223-232, MIT (1977)		
	NPL72	Wright, A., and Morrison, S.L., "Effect of glycosylation on antibody function: implications for genetic engineering," <i>Trends Biotechnol.</i> 15:26-32, Eslevier Science Ltd. (1997)		
	NPL73	Wormland, M.R., <i>et al.</i> , "Variations in Oligosaccharide-Protein Interactions in Immunoglobulin G Determine the Site-Specific Glycosylation Profiles and Modulate the Dynamic Motion of the Fc Oligosaccharides," <i>Biochemistry</i> 36:1370-1380, American Chemical Society (1997)		
	NPL74	Zecca, M., <i>et al.</i> , "Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated pure red cell aplasia and hemolytic anemia," <i>Blood</i> 97:3995-3997, The American Society of Hematology (2001)		

763165v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.